TransMedics Group, Inc. TMDX is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System (“OCS”) technology. The optimism, led by solid third-quarter 2025 results, ...

TransMedics Group (NASDAQ: TMDX) was a top-performing stock that more than doubled in value during the months between the end of 2023 and late August. Unfortunately, shares of the healthcare stock ...

TransMedics grew sales by 38% during the second quarter and saw its profit margins double compared to last year. Despite this, there may still be room for improvement, according to its CEO.

Abivax is preparing a regulatory submission in the U.S. in the second half of 2026, provided an ongoing maintenance trial also hits the mark. It will also target other indications for obefazimod, ...

TransMedics Group's Organ Care System (OCS) is transforming organ transplantation. The company should be well-positioned to dominate the organ transplant market for decades. TransMedics believes it ...

ANDOVER, Mass., Aug. 4, 2025 /PRNewswire/ -- TransMedics Group, Inc. (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and ...

Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion ...

Scorpion Capital, on Friday, disclosed a short seller report on TransMedics Group Inc (NASDAQ:TMDX), accusing the organ transplant technology company of fraudulent practices, including kickbacks, ...

Shares of leading organ transplant technology company TransMedics (NASDAQ: TMDX) rose 15% as of noon ET on Thursday, according to data provided by S&P Global Market Intelligence. TransMedics reported ...